Disease relevance of Scleroderma, Systemic

• We studied D-penicillamine toxicity in 259 patients with systemic sclerosis treated since 1972 [1].
• Pemphigus and myasthenia gravis may occur more frequently with therapy for systemic sclerosis than with that for rheumatoid arthritis [1].
• Nailfold capillary microscopy in mixed connective tissue disease. Comparison with systemic sclerosis and systemic lupus erythematosus [2].
• Seven of these patients were diagnosed as having Sjögren's syndrome, 4 had concomitant rheumatoid arthritis, 1 had concomitant systemic sclerosis (SSc), and 2 had SSc alone [3].
• Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse [4].

Psychiatry related information on Scleroderma, Systemic

• OBJECTIVE: To determine if men with systemic sclerosis (SSc) are at increased risk of developing erectile dysfunction (ED) compared to men with rheumatoid arthritis (RA), and to investigate the temporal relationship of ED related to rheumatologic disease [5].

High impact information on Scleroderma, Systemic

• Furthermore, Y-chromosome sequences were identified in skin-biopsy specimens from 11 of 19 women with systemic sclerosis (58 percent); 9 of the 11 were known to have carried male fetuses [6].
• Autoantibodies specific against fibrillarin, a 34-kD nucleolar protein associated with U3-snRNP, are present in patients with systemic sclerosis (SSc) [7].
• Working with cultured dermal fibroblasts derived from control individuals and patients with systemic sclerosis (SSc), we have examined the effects of protein kinase C-delta (PKC-delta) on type I collagen biosynthesis and steady-state levels of COL1A1 and COL3A1 mRNAs [8].
• AECA-positive/anti-PL antibody-negative sera from eight patients with systemic sclerosis (SS) and 21 control patients were evaluated [9].
• Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III [10].

Chemical compound and disease context of Scleroderma, Systemic

• Prostacyclin increases cyclic-nucleotide responsiveness of lymphocytes from patients with systemic sclerosis [11].
• Absence of prostaglandin stimulated increase in acute phase proteins in systemic sclerosis [12].
• Low cyclic-AMP levels within lymphocytes from five patients with systemic sclerosis showed a striking increase in response to isoprenaline after intravenous infusion of prostacyclin [11].
• Although toxic, with a high frequency of adverse effects, D-penicillamine can be used safely in the treatment of systemic sclerosis [1].
• Diffusing capacity of the lung and nifedipine in systemic sclerosis [13].

Biological context of Scleroderma, Systemic

• To examine whether microchimerism occurs in Japanese women patients with systemic sclerosis, we analysed the Y-chromosome in DNA by PCR [14].
• Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis [15].
• OBJECTIVE: As an initial approach to understanding the basis of the systemic sclerosis (SSc; scleroderma) phenotype, we sought to identify genes in the transforming growth factor beta (TGF beta) signaling pathway that are up-regulated in lesional SSc fibroblasts relative to their normal counterparts [16].
• Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic associations in systemic sclerosis [17].
• Because targeting of TGFbeta signaling represents a potential approach to the treatment of systemic sclerosis (SSc) and other fibrotic disorders, we investigated the modulation of intracellular TGFbeta signal transduction by SB431542, the first small-molecule inhibitor of ALK-5 to be described [18].

Anatomical context of Scleroderma, Systemic

• These findings are similar to those described for fibroblasts from humans with systemic sclerosis and validate the use of Tsk2 as a model for the study of the connective tissue alterations in this disease [19].
• OBJECTIVE: To determine serum levels of BAFF, a potent B cell survival factor, in patients with systemic sclerosis (SSc) and relate the results to the clinical features of SSc [20].
• Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen [21].
• Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis [22].
• Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis [23].

Gene context of Scleroderma, Systemic

• Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma) [24].
• Relative to normal pulmonary fibroblasts, fibroblasts cultured from scars of patients with the fibrotic disease systemic sclerosis (scleroderma) show enhanced ET-1 expression and binding [25].
• Examination of the possible role of biologically relevant genes around FBN1 in systemic sclerosis in the Choctaw population [26].
• Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis [27].
• OBJECTIVE: To describe the histopathologic and biochemical characteristics of skin from the Tsk2/+ mouse, a mutation with phenotypic features resembling those of systemic sclerosis (SSc), and to report the initial genetic mapping of the Tsk2 locus [28].

Analytical, diagnostic and therapeutic context of Scleroderma, Systemic

• METHODS: We used the polymerase chain reaction (PCR) to identify Y-chromosome sequences in DNA extracted from peripheral-blood cells and skin lesions from women with systemic sclerosis of recent onset [6].
• The role of transforming growth factor beta 2 (TGF-beta 2) in the pathogenesis of systemic sclerosis (SSc) was investigated by in situ hybridization of skin biopsies from six patients with SSc [29].
• Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis [30].
• The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study [31].
• Immunofluorescence on rat liver sections was used to select high-titer antinucleolar antibodies (ANoA) in the sera of patients with systemic sclerosis (scleroderma) [32].

References